A randomized controlled study of a combination of internal and external treatments for albumin paclitaxel-related peripheral neurotoxicity

Shanxi Institute of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•?Patients who have pathologically or cytologically confirmed lung cancer or breast cancer.
•?Patients' age 18-80 years, regardless of gender.
•?Patients with a KPS score = 60 and an expected survival of not less than 3 months.
•?Patients who have developed peripheral neurotoxicity after receiving albumin paclitaxel treatment.
•? no major visceral organ dysfunction and no cardiovascular or cerebrovascular complications.
•? Skin of all four limbs is intact.
•? Those who can understand the situation of this study, voluntarily accept the TCM treatment and voluntarily accept the questionnaire for good compliance.

•?Patients with reduced platelets prone to bleeding.
•?Those who do not meet the above inclusion criteria.
•?Patients who have symptoms related to nerve compression due to brain metastases or who have peripheral nerve damage due to tumour compression.
•?Patients with other previous peripheral neuropathies, e.g. neurological diseases, orthopaedic related diseases, peripheral neuropathies due to circulatory disorders.
•? those with a history of allergy to drug exposure or the presence of skin lesions on the hands and feet (e.g. eczema).
•? Those who are unable to cooperate with treatment.
•?Women during pregnancy or breastfeeding.
•?Those currently or within 4 weeks participating in other clinical trials.
•?Allergic individuals who are susceptible to hypersensitivity to the drug.

发起方

Shanxi Institute of Traditional Chinese Medicine